Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2030

Conditions
Pediatric Cancer
Interventions
BIOLOGICAL

Vaccine

Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.

Trial Locations (1)

28204

RECRUITING

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER